Sanofi Pasteur to Contribute to Pocono Health System

(3BL Media / theCSRfeed) East Stroudsburg, PA – March 2, 2012 – Today, Sanofi Pasteur demonstrated its commitment to Pocono Health System and the Pocono Mountains community as the company announced its donation to benefit the new Dale and Frances Hughes Cancer Center. The $500,000 contribution, presented by Frank Epifano, vice president, North America and Global Finance Commercial Operations, Sanofi Pasteur; and Phil Hosbach, vice president, Immunization Policy, Sanofi Pasteur; will be used toward the construction of the Center.

“We are extremely grateful to have received this generous donation from Sanofi Pasteur for the new Hughes Cancer Center -- a project vitally important to our community as cancer rates grow four percent each year in Monroe County,” said Kathleen E. Kuck, president and CEO of Pocono Health System/Pocono Medical Center (PMC). “The new, state-of-the-art Center allows us to bring our world-class technology, protocols, physicians and staff under one roof, close to home for our patients.”

The design of the new Hughes Cancer Center will offer a healing environment, contributing to the health, well-being and optimism of local cancer patients and their families. The Center, which is scheduled to be completed this year -- complemented by an expansion of PMC oncology service staff -- will meet a critical need in the region, as cancer has now become the leading cause of death in Monroe County, according to the Pennsylvania Department of Health 2011 County Health Profile.

“Sanofi Pasteur is honored to partner with and contribute to Pocono Health System’s new Dale and Frances Hughes Cancer Center,” said Hosbach. “As a member of the System’s Board of Directors, I have seen firsthand the important and admirable accomplishments of this organization, and in particular, how their life-saving work aligns with our goals and interests at Sanofi Pasteur. We look forward to continuing our collaborative efforts toward a healthier Monroe County and a strengthened Pennsylvania.”

Kuck added, “I would like to thank the entire Sanofi Pasteur team for their kind support of this project and remind them how the lives of tomorrow’s cancer patients and their families will be significantly impacted in a positive way because of Sanofi Pasteur’s efforts in making the new Hughes Cancer Center a reality.”

Sanofi Pasteur’s collective contributions to Pocono Health System -- including today’s donation, have supported critical areas such as oncology, cardiovascular health and the construction of the Mountain Healthcare facility. These donations mark just one example of Sanofi Pasteur’s steadfast commitment to local Corporate Social Responsibility.

Other highlights include the company and its employees exceeding $1 million in philanthropic giving in 2009, 2010, and again in 2011, supporting hundreds of other local non-profit organizations. The company also strengthens the local community through spearheading efforts such as the annual Pocono Mountains Community Fundraiser, which has benefitted thousands of local residents. More company information is available at the Sanofi Pasteur Community Relations website: http://community.sanofipasteur.us.

About Sanofi Pasteur
Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.com  or www.sanofipasteur.us

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2010. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.